stock-detail (BPTH)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/24/2017 06:17 pm

4/24/2017 06:17 pm

4/24/2017 06:17 pm

4/17/2017 06:17 am

4/17/2017 06:17 am

Bio-Path reports 4Q loss

3/15/2017 11:03 am

Bio-Path reports 4Q loss

3/15/2017 11:03 am

Bio-Path Holdings Reports Full Year 2016 Financial Results

3/15/2017 11:00 am

[GlobeNewswire] - HOUSTON, March 15, 2017-- Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid ...

Bio-Path Holdings to Present at the Oppenheimer 27th Annual Healthcare Conference

3/14/2017 12:00 pm

[GlobeNewswire] - HOUSTON, March 14, 2017-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic ...

Bio-Path Holdings Announces Rescheduled Date and Time of Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017

3/13/2017 12:00 pm

[GlobeNewswire] - HOUSTON, March 13, 2017-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic ...

Bio-Path Holdings to Present Data at the 2017 AACR Annual Meeting

3/10/2017 01:00 pm

[GlobeNewswire] - HOUSTON, March 10, 2017-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic ...

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2016 Financial Results on March 14, 2017

3/9/2017 09:00 pm

[GlobeNewswire] - HOUSTON, March 09, 2017-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic ...

Bio-Path Holdings Appoints Dr. Craig Hooper to Scientific Advisory Board

2/21/2017 01:00 pm

[GlobeNewswire] - HOUSTON, Feb. 21, 2017-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid ...

Bio-Path Holdings to Present at the 19th Annual BIO CEO & Investor Conference

2/7/2017 01:00 pm

[GlobeNewswire] - HOUSTON, Feb. 07, 2017-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid ...